Targeted therapies

drugs targeting HER-2, EGFR, VEGF, MEK, BRAF, mTOR, BCR-ABL, Bruton tyrosine kinase, CD20

 AND proteasome inhibitors, immunomodulators (-imids)

Cardio-oncological evaluation* (troponin** if IV/SC)

before cancer therapy begins

IV or SC



after each cycle (end of infusion)

Troponin +

Troponin -

Cardio-oncological evaluation*

every 3 months during the 1st year and on a case-by-case basis afterwards

Cardio-oncological evaluation*

before the next cycle

* A cardio-ocological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.


**Assays should be carried out by the same laboratory (same type of troponin, same method of measurement).

Troponin + if >99e percentile of the URL

Logo final.png

Centre Méditerranéen Hospitalo-Universitaire de Cardio-Oncologie

​Hôpital Nord, chemin des Bourrely, 13015 Marseille, France

Aix-Marseille Université

Nous contacter

  • Facebook Social Icône


© 2020 by Franck Thuny